Amgen Acquisitions: How the Biotech Giant Expanded Its Therapeutics Portfolio

Amgen acquisitions show how one of the world’s leading biotechnology companies expanded across rare disease, oncology, inflammation, autoimmune disease, genetics, kidney disease, cardiovascular research, regenerative medicine, and specialty therapeutics.

Amgen is not a traditional pharmaceutical company built mainly on chemical drugs. It is a biotechnology pioneer known for developing and manufacturing human therapeutics. Its acquisition strategy reflects that identity. Most of its listed deals are biotechnology or biopharmaceutical acquisitions.

According to the uploaded acquisition data, Amgen made 17 acquisitions between 2000 and 2022. These deals had a total disclosed value of $63.6 billion and an average disclosed deal size of $3.7 billion. The most active acquisition sectors were biotechnology, healthcare, medical, biopharma, and therapeutics.

The largest listed acquisition was Horizon Pharma, also known as Horizon Therapeutics, announced in December 2022 for $27.8 billion. Amgen completed that acquisition in October 2023. Other major listed acquisitions include Otezla, Onyx Pharmaceuticals, ChemoCentryx, Five Prime Therapeutics, Tularik, BioVex, TeneoBio, MN Pharmaceuticals, DeCODE Genetics, Ilypsa, Avidia, KAI Pharmaceuticals, Dezima Pharma, Alantos Pharmaceuticals, Rodeo Therapeutics, and Kinetix Pharmaceuticals.

This article explains the Amgen acquisitions timeline, the biggest deals, the company’s most active sectors, and the strategic lessons behind Amgen’s long-running biotechnology M&A strategy.

What Is Amgen?

Amgen is a biotechnology company that develops and manufactures human therapeutics for serious illnesses and diseases. The company is known for biologic medicines, specialty drugs, and advanced therapeutic research.

Amgen’s business spans several major areas, including:

• Oncology.
• Inflammation.
• Rare disease.
• Nephrology.
• Cardiovascular disease.
• Bone health.
• Autoimmune disease.
• Human genetics.
• Biologic medicines.
• Specialty therapeutics.

The company’s acquisition strategy supports its scientific focus. Instead of buying unrelated businesses, Amgen usually acquires companies or assets that strengthen its therapeutic pipeline, add commercial medicines, expand research platforms, or deepen its position in serious disease areas.

That is why biotechnology appears as the leading acquisition sector in the uploaded dataset.

Why Amgen Acquisitions Matter

Amgen acquisitions matter because biotechnology companies face constant pressure to renew their pipelines.

Drug development is expensive, slow, and risky. A company may spend years developing a medicine that later fails in clinical trials. Even successful products can face patent expirations, competition, pricing pressure, and changing treatment standards.

Acquisitions help Amgen address those challenges.

The company has used M&A to:

• Add commercial medicines.
• Expand into rare disease.
• Strengthen oncology.
• Add autoimmune and inflammatory disease assets.
• Deepen human genetics capabilities.
• Add antibody and protein technology platforms.
• Strengthen cardiovascular and kidney disease research.
• Enter new therapeutic areas.
• Reduce dependence on older products.
• Add pipeline candidates with long-term potential.

However, biotech acquisitions carry risk. Clinical programs may fail. Commercial products may underperform. Regulators may require conditions. Payers may push back on pricing. Integration can be difficult.

The Horizon acquisition is a good example of both opportunity and scrutiny. The FTC challenged the transaction before later finalizing a consent order that resolved potential competitive concerns.

Full List of Amgen Acquisitions

The uploaded dataset lists 17 Amgen acquisitions from 2000 to 2022. The table below summarizes the deals, values, sectors, and strategic relevance.

This acquisition list shows Amgen’s clear focus on biotech and serious disease areas.

Amgen Acquisitions Timeline

Amgen’s acquisition timeline can be divided into several phases: early research-platform expansion, therapeutic protein and small-molecule additions, oncology growth, genetics expansion, inflammation and rare disease expansion, and antibody-platform building.

2000: Kinetix Pharmaceuticals

Amgen acquired Kinetix Pharmaceuticals in October 2000 for $170.0 million.

Kinetix specialized in discovering small molecules in the field of protein kinase inhibition. Kinases are important because they help regulate many biological processes, including cell growth and signaling.

Kinase inhibitors later became important in cancer and other disease areas. The acquisition gave Amgen exposure to small-molecule discovery in a field that became highly relevant to modern medicine.

This deal showed that Amgen was willing to expand beyond biologics into targeted small-molecule research.

2004: Tularik

Amgen acquired Tularik in March 2004 for $1.3 billion.

Tularik focused on discovering and developing orally available medicines that act through the regulation of gene expression.

This acquisition strengthened Amgen’s research capabilities. Gene expression is central to disease biology because it influences how cells behave and respond to treatment.

Tularik also helped Amgen expand into orally available medicines, which can be attractive because patients often prefer pills over injections when clinically appropriate.

2006: Avidia

Amgen acquired Avidia in October 2006 for $380.0 million.

Avidia was a biopharmaceutical company focused on discovering and developing therapeutic proteins.

This acquisition fit Amgen’s biotech identity. Therapeutic proteins are important in many serious diseases because they can target biological pathways with high specificity.

Avidia strengthened Amgen’s research platform and biologic drug development capability.

2007: Ilypsa and Alantos Pharmaceuticals

In 2007, Amgen acquired Ilypsa and Alantos Pharmaceuticals.

Ilypsa was acquired in June 2007 for $420.0 million. It was a biotechnology company involved in discovering, developing, manufacturing, and delivering human therapeutics.

Alantos Pharmaceuticals was acquired the next day for $300.0 million. It was an international biopharmaceutical company focused on developing small-molecule pharmaceuticals.

These two deals show Amgen’s balanced approach. Ilypsa strengthened biotech and human therapeutics, while Alantos added small-molecule pharmaceutical research.

Amgen Expands Oncology and Genetics

From 2011 to 2013, Amgen made major acquisitions that strengthened oncology, kidney disease, cardiovascular research, and genetics.

2011: BioVex

Amgen acquired BioVex in January 2011 for $1.0 billion.

BioVex developed and commercialized biological treatments for cancer and infectious diseases.

This acquisition strengthened Amgen’s oncology strategy. Biological treatments can help target cancer through immune or viral-based approaches.

BioVex was important because oncology became one of the most competitive and valuable areas in biotechnology. Amgen needed strong cancer assets to compete with other major biopharmaceutical companies.

2012: KAI Pharmaceuticals

Amgen acquired KAI Pharmaceuticals in April 2012 for $315.0 million.

KAI discovered and developed novel therapeutics for cardiovascular diseases, kidney diseases, and pain.

This acquisition fit Amgen’s existing strength in nephrology and serious chronic diseases. Kidney disease patients often have complex treatment needs, and Amgen already had experience in related markets.

2012: MN Pharmaceuticals

Amgen acquired MN Pharmaceuticals in April 2012 for $700.0 million.

MN Pharmaceuticals supplied pharmaceuticals to hospitals in Turkey.

This deal gave Amgen market and distribution exposure outside the United States. It also strengthened the company’s international healthcare presence.

For a global biotechnology company, regional access can matter. Medicines need distribution, hospital relationships, regulatory knowledge, and local market infrastructure.

2012: DeCODE Genetics

Amgen acquired DeCODE Genetics in December 2012 for $415.0 million.

DeCODE Genetics developed and offered diagnostic tests for gene variants. The company was known for human genetics research.

This acquisition was strategically important because human genetics can improve drug discovery. If researchers understand genetic links to disease, they may identify better targets, reduce development risk, and design more precise treatments.

DeCODE strengthened Amgen’s ability to use genetic data in drug discovery and disease understanding.

2013: Onyx Pharmaceuticals

Amgen acquired Onyx Pharmaceuticals in August 2013 for $10.5 billion.

Onyx was a biopharmaceutical company focused on improving the lives of people with cancer. This was one of Amgen’s largest acquisitions.

The deal strengthened Amgen’s oncology portfolio and added commercial cancer medicines. Oncology is a major growth market, but it is also highly competitive and research-intensive.

Onyx helped Amgen become more important in cancer treatment and gave it a stronger commercial oncology platform.

Amgen Expands Cardiovascular and Inflammation Assets

The next major phase included cardiovascular research and a major inflammation product.

2015: Dezima Pharma

Amgen acquired Dezima Pharma in September 2015 for $300.0 million.

Dezima developed protein-based compounds for treating cardiovascular disease related to dyslipidemia.

Dyslipidemia involves abnormal levels of blood lipids, such as cholesterol and triglycerides. It is an important cardiovascular risk factor.

This acquisition strengthened Amgen’s cardiovascular research focus.

2019: Otezla

In November 2019, Amgen acquired Otezla for $13.4 billion.

Otezla is a prescription medicine approved for patients with moderate inflammatory disease indications. The uploaded dataset describes it as an approved prescription medicine.

Otezla was strategically important because it was a marketed product, not just a clinical-stage asset. It helped Amgen expand in inflammation and immunology.

The acquisition came after Bristol Myers Squibb and Celgene needed to divest Otezla as part of regulatory approval for their merger. Amgen bought the product and added a significant commercial medicine to its portfolio.

This was Amgen’s second-largest listed acquisition after Horizon.

Amgen’s 2021 Biotech Acquisition Wave

In 2021, Amgen made three visible acquisitions: Five Prime Therapeutics, Rodeo Therapeutics, and TeneoBio.

Five Prime Therapeutics

Amgen acquired Five Prime Therapeutics in March 2021 for $1.9 billion.

Five Prime was a clinical-stage biotechnology company developing cancer treatments.

This deal strengthened Amgen’s oncology pipeline. Cancer remains a major strategic area for biotech companies because there is high unmet need and constant scientific progress.

Five Prime added clinical-stage assets that could support Amgen’s long-term cancer strategy.

Rodeo Therapeutics

Amgen acquired Rodeo Therapeutics in March 2021 for $55.0 million.

Rodeo developed small-molecule therapies designed to promote regeneration and repair of multiple tissue types.

This was a smaller acquisition, but it added a focused therapeutic platform. Regenerative medicine and tissue repair can support treatment areas where the body needs help restoring damaged tissue.

TeneoBio

Amgen acquired TeneoBio in July 2021 for $900.0 million.

TeneoBio specialized in developing human heavy-chain antibodies.

Antibody platforms are important in biotechnology because they can generate medicines that target disease-related proteins with precision. Heavy-chain antibody technology can support new formats and therapeutic approaches.

This acquisition strengthened Amgen’s antibody engineering capabilities.

Amgen Expands Autoimmune and Rare Disease Portfolio

The most recent acquisitions in the uploaded dataset show Amgen expanding further into autoimmune, inflammatory, and rare disease markets.

2022: ChemoCentryx

Amgen acquired ChemoCentryx in August 2022 for $3.7 billion.

ChemoCentryx was a biopharmaceutical company that developed medicines for inflammatory and autoimmune diseases and cancer.

This acquisition strengthened Amgen’s inflammation and autoimmune disease portfolio. Autoimmune diseases often require long-term treatment, and therapies that reduce inflammation can become important commercial products.

The ChemoCentryx deal gave Amgen additional specialty medicine exposure.

2022–2023: Horizon Therapeutics

Amgen announced the acquisition of Horizon Therapeutics in December 2022 for $27.8 billion. Horizon focused on prescription drugs for rare and serious diseases.

Amgen completed the acquisition on October 6, 2023, for $116.50 per share in cash, representing an equity value of about $27.8 billion.

The Horizon deal was transformational. It expanded Amgen’s rare disease portfolio and added medicines for serious conditions with significant unmet need.

However, the acquisition also faced regulatory scrutiny. The FTC approved a final consent order in December 2023 resolving potential competitive concerns related to the acquisition.

This deal shows both the scale and complexity of modern biopharma M&A.

Biggest Amgen Acquisitions by Deal Value

The largest Amgen acquisitions show where the company made its biggest strategic commitments.

These top deals show Amgen’s major priorities: rare disease, inflammation, oncology, autoimmune disease, genetics, biologics, and specialty therapeutics.

Most Common Amgen Acquisition Sectors

The uploaded dataset identifies biotechnology, healthcare, medical, biopharma, and therapeutics as Amgen’s most frequent acquisition sectors.

This sector mix shows that Amgen’s acquisition strategy is tightly connected to its identity as a biotechnology company.

Strategic Lessons From Amgen Acquisitions

Amgen’s acquisition history offers several useful lessons about biotech M&A.

Amgen Uses M&A to Refresh Its Pipeline

Biotech companies need new products because older medicines eventually face competition or patent pressure.

Amgen acquisitions added pipeline assets, commercial medicines, and research platforms. This helped the company reduce dependence on internal discovery alone.

Oncology Has Been a Major Priority

BioVex, Onyx, and Five Prime all strengthened Amgen’s oncology strategy.

Oncology is attractive because cancer remains a major global health challenge. However, it is also highly competitive and scientifically demanding.

Rare Disease Became More Important

Horizon Therapeutics moved Amgen deeper into rare disease.

Rare disease medicines can address serious unmet needs. They may also offer strong commercial potential when products are differentiated and serve small but high-need patient populations.

Human Genetics Can Improve Drug Discovery

DeCODE Genetics strengthened Amgen’s genetic research capability.

Genetics can help identify disease targets, validate biological pathways, and improve research productivity.

Antibody Platforms Support Future Innovation

TeneoBio added heavy-chain antibody technology.

Antibodies are central to modern biotech. Platform acquisitions can support multiple future programs rather than only one product.

Big Biopharma Deals Face Regulatory Scrutiny

The Horizon acquisition faced FTC action before being resolved through a consent order. This shows that large biopharma acquisitions are now watched closely by regulators.

How Amgen Acquisitions Fit the Biotechnology Market

The biotechnology market depends on innovation. Companies must discover, develop, test, manufacture, and commercialize medicines for serious diseases.

Amgen acquisitions fit this market because they add several types of value:

• Approved medicines.
• Clinical-stage assets.
• Research platforms.
• Antibody technology.
• Genetic data.
• International reach.
• Oncology pipelines.
• Rare disease products.
• Inflammation and autoimmune therapies.

This allows Amgen to balance commercial assets with long-term research bets.

For example, Otezla added a marketed inflammation product. Onyx added oncology strength. Horizon added rare disease medicines. DeCODE added genetics. TeneoBio added antibody technology. Five Prime added oncology pipeline assets.

Together, these deals show a portfolio-building strategy.

Competitive Impact of Amgen Acquisitions

Amgen competes with major pharmaceutical and biotechnology companies in oncology, inflammation, rare disease, nephrology, cardiovascular disease, and other specialty areas.

Acquisitions help Amgen compete in several ways.

First, they add differentiated medicines. Horizon and Otezla added commercial products.

Second, they add scientific platforms. DeCODE and TeneoBio strengthened research capability.

Third, they add pipeline options. Five Prime, BioVex, KAI, and Rodeo added development programs.

Fourth, they strengthen therapeutic-area depth. Onyx helped oncology, ChemoCentryx helped autoimmune and inflammatory disease, and Horizon helped rare disease.

Fifth, they help Amgen respond to patent and competitive pressure.

However, acquisitions do not guarantee success. Amgen must keep investing in clinical development, regulatory approvals, manufacturing, market access, and physician adoption.

Advantages of Amgen’s Acquisition Strategy

Amgen acquisitions created several advantages.

Stronger Rare Disease Portfolio

Horizon added rare disease medicines and specialty assets.

Deeper Oncology Position

Onyx, BioVex, and Five Prime strengthened cancer-related capabilities.

Broader Inflammation and Autoimmune Exposure

Otezla and ChemoCentryx expanded Amgen’s role in inflammatory and autoimmune disease markets.

Better Research Platforms

DeCODE added genetics, while TeneoBio added antibody technology.

More Commercial Diversification

Large product acquisitions such as Otezla and Horizon helped diversify revenue sources.

Faster Access to Innovation

Acquisitions allowed Amgen to access external science without developing every asset internally from the beginning.

Disadvantages of Amgen’s Acquisition Strategy

The strategy also carries risks.

Clinical Failure Risk

Pipeline acquisitions can fail in clinical trials.

High Purchase Prices

Large deals such as Horizon, Otezla, Onyx, and ChemoCentryx required major capital.

Integration Risk

Amgen must integrate teams, products, manufacturing, research programs, and commercial operations.

Regulatory Scrutiny

The Horizon deal showed that regulators may challenge large biopharma transactions.

Reimbursement Pressure

Specialty medicines can face payer scrutiny, especially if prices are high.

Pipeline Uncertainty

Scientific promise does not always turn into approved products or commercial success.

Case Studies of Major Amgen Acquisitions

Several Amgen acquisitions stand out because of their size and strategic impact.

Horizon Therapeutics

Horizon Therapeutics was Amgen’s largest acquisition at $27.8 billion.

The deal expanded Amgen into rare disease medicines and added a portfolio focused on serious conditions with high unmet need.

Amgen completed the acquisition in October 2023. The FTC later finalized a consent order resolving competitive concerns linked to the transaction.

Otezla

Otezla was acquired for $13.4 billion.

The acquisition added an approved medicine for inflammatory disease. It strengthened Amgen’s commercial portfolio and gave the company a major product in immunology and inflammation.

Onyx Pharmaceuticals

Onyx was acquired for $10.5 billion.

The deal strengthened Amgen’s oncology position. Onyx was focused on improving the lives of people with cancer and brought important cancer treatment assets into Amgen’s portfolio.

ChemoCentryx

ChemoCentryx was acquired for $3.7 billion.

The company developed medicines for inflammatory and autoimmune diseases and cancer. The acquisition expanded Amgen’s specialty medicine portfolio.

Five Prime Therapeutics

Five Prime was acquired for $1.9 billion.

The company developed cancer treatments. This acquisition strengthened Amgen’s oncology pipeline.

DeCODE Genetics

DeCODE was acquired for $415.0 million.

The company added human genetics and diagnostic testing expertise. It helped Amgen use genetic data to improve drug discovery.

TeneoBio

TeneoBio was acquired for $900.0 million.

The company specialized in human heavy-chain antibodies. This acquisition strengthened Amgen’s antibody platform.

BioVex

BioVex was acquired for $1.0 billion.

The company developed biological treatments for cancer and infectious diseases. It expanded Amgen’s biologic oncology capabilities.

Business Lessons From Amgen Acquisitions

Amgen’s acquisition history offers useful lessons for biotechnology companies, investors, and business readers.

External Innovation Matters

Large biotech companies cannot rely only on internal research. Acquisitions help bring in external science, platforms, and commercial assets.

Commercial Assets Can Reduce Risk

Buying approved products such as Otezla can be less risky than buying only clinical-stage assets, although valuation risk remains.

Platform Deals Can Create Long-Term Value

DeCODE and TeneoBio added capabilities that can support multiple future programs.

Therapeutic Focus Matters

Amgen’s acquisitions are concentrated in biotech, oncology, inflammation, rare disease, genetics, and specialty therapeutics. This focus supports strategic clarity.

Regulatory Risk Is Rising

The Horizon deal shows that even non-overlapping biopharma acquisitions can face scrutiny if regulators believe the buyer could use market power to weaken future competition.

Key Takeaways

• Amgen acquisitions helped the company expand across rare disease, oncology, inflammation, autoimmune disease, genetics, and biotechnology.
• The uploaded dataset states that Amgen made 17 acquisitions from 2000 to 2022.
• Total disclosed deal value was $63.6 billion.
• Average disclosed deal size was $3.7 billion.
• Biotechnology was the most frequent sector, with 16 deals.
• Health care appeared eight times.
• Medical appeared seven times.
• Horizon Therapeutics was the largest acquisition at $27.8 billion.
• Amgen completed the Horizon acquisition on October 6, 2023.
• Otezla was the second-largest listed acquisition at $13.4 billion.
• Onyx Pharmaceuticals strengthened Amgen’s oncology business.
• DeCODE Genetics strengthened human genetics research.
• TeneoBio added heavy-chain antibody technology.
• ChemoCentryx expanded autoimmune and inflammatory disease exposure.
• The main risks include clinical failure, high purchase prices, regulatory scrutiny, reimbursement pressure, and integration complexity.

Frequently Asked Questions

How many acquisitions has Amgen made?

The uploaded dataset states that Amgen made 17 acquisitions between 2000 and 2022.

What is the total disclosed value of Amgen acquisitions?

The dataset lists total disclosed deal value of $63.6 billion.

What is the average Amgen acquisition size?

The dataset lists the average disclosed deal size as $3.7 billion.

What was Amgen’s most recent acquisition in the dataset?

The most recent acquisition in the uploaded dataset was Horizon Pharma, also known as Horizon Therapeutics, announced in December 2022 for $27.8 billion.

Did Amgen complete the Horizon Therapeutics acquisition?

Yes. Amgen completed the acquisition of Horizon Therapeutics on October 6, 2023, for $116.50 per share in cash, representing an equity value of about $27.8 billion.

What was Amgen’s largest acquisition?

The largest acquisition in the uploaded dataset was Horizon Therapeutics at $27.8 billion.

Why did Amgen acquire Horizon Therapeutics?

Amgen acquired Horizon to expand its rare disease portfolio and add first-in-class medicines for serious conditions.

Why did Amgen acquire Otezla?

Amgen acquired Otezla to add an approved medicine for inflammatory disease and strengthen its immunology and inflammation portfolio.

Why did Amgen acquire Onyx Pharmaceuticals?

Amgen acquired Onyx to strengthen its oncology business and add cancer treatment assets.

Why did Amgen acquire DeCODE Genetics?

Amgen acquired DeCODE Genetics to strengthen human genetics research and improve drug discovery.

Why did Amgen acquire TeneoBio?

Amgen acquired TeneoBio to add human heavy-chain antibody technology and strengthen its antibody development platform.

What sectors does Amgen acquire most often?

The uploaded dataset lists biotechnology, healthcare, medical, biopharma, and therapeutics as the most common sectors.

Did regulators challenge the Horizon acquisition?

Yes. The FTC challenged the Horizon acquisition before the matter was resolved. The FTC finalized a consent order in December 2023 to resolve potential competitive concerns.

What are the risks of Amgen acquisitions?

The main risks include clinical trial failure, regulatory scrutiny, high purchase prices, reimbursement pressure, integration challenges, and uncertain commercial performance.

What can investors learn from Amgen acquisitions?

Investors can learn how a biotechnology company uses M&A to refresh its pipeline, add commercial medicines, expand therapeutic areas, and strengthen research platforms.

Suggested Internal Links

Use these internal link ideas if your website has related content:

• Amgen company profile
• Biggest biotechnology acquisitions
• What is biopharma?
• Oncology drug development explained
• Rare disease medicines guide
• Pharmaceutical M&A explained
• Human genetics in drug discovery
• Antibody therapeutics explained
• FDA drug approval process
• How mergers and acquisitions work

Suggested External Sources

Use these authoritative external sources for added credibility:

• Amgen investor relations
• Amgen press releases
• U.S. Securities and Exchange Commission filings
• U.S. Federal Trade Commission merger resources
• U.S. Food and Drug Administration resources
• European Medicines Agency resources
• ClinicalTrials.gov
• National Institutes of Health genetics resources
• Investopedia guide to mergers and acquisitions
• World Health Organization health data

Conclusion

Amgen acquisitions show how a biotechnology leader used M&A to expand across rare disease, oncology, inflammation, autoimmune disease, genetics, antibody technology, cardiovascular research, and specialty therapeutics.

The uploaded dataset lists 17 acquisitions from 2000 to 2022, with total disclosed value of $63.6 billion and an average deal size of $3.7 billion. The largest deal was Horizon Therapeutics at $27.8 billion, followed by Otezla at $13.4 billion and Onyx Pharmaceuticals at $10.5 billion.

The strategy reveals Amgen’s priorities. Horizon strengthened rare disease. Otezla strengthened inflammation. Onyx strengthened oncology. DeCODE strengthened human genetics. TeneoBio added antibody technology. ChemoCentryx expanded autoimmune and inflammatory disease exposure.

The main lesson is clear. Amgen acquisitions are not random. They support a focused biotechnology strategy built around serious diseases, scientific platforms, commercial medicines, and long-term pipeline renewal. However, success depends on clinical results, regulatory approvals, market access, integration, and disciplined capital allocation.

Read Also: AMETEK Acquisitions: How the Industrial Technology Company Built a Precision Portfolio